| gap-debate-20260417- | Can NLRP3 inflammasome inhibition modify disease progression in symptomatic AD p | open | 0.79 | 0.72 | 2026-04-17 | 0 | | immunology |
| gap-debate-20260417- | Why are basal forebrain cholinergic neurons selectively vulnerable compared to o | open | 0.75 | 0.70 | 2026-04-17 | 0 | | molecular-biology |
| gap-debate-20260417- | What determines the temporal sequence of cholinergic dysfunction versus amyloid/ | partially_addressed | 0.88 | 0.69 | 2026-04-17 | 1 | 2026-04-25 | neurodegeneration |
| gap-debate-20260417- | Does α7-nAChR blockade or agonism provide optimal therapeutic benefit in AD prog | open | 0.82 | 0.71 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | Which complement pathway components show the strongest correlation with PV inter | open | 0.69 | 0.68 | 2026-04-17 | 0 | | neuroinflammation |
| gap-debate-20260417- | What is the cell-type-specific expression pattern of LDHB in PV interneurons ver | open | 0.71 | 0.66 | 2026-04-17 | 0 | | metabolic-neuroscience |
| gap-debate-20260417- | Can PARP inhibitors achieve therapeutic CNS exposure without causing peripheral | open | 0.78 | 0.63 | 2026-04-17 | 0 | | drug-development |
| gap-debate-20260417- | Does ID2 directly cause PV interneuron dysfunction in adult AD brains, or are PV | open | 0.82 | 0.66 | 2026-04-17 | 0 | | neurodegeneration |
| gap-debate-20260417- | How can small molecule therapeutics effectively cross the blood-spinal cord barr | open | 0.75 | 0.68 | 2026-04-17 | 0 | | pharmacology |
| gap-debate-20260417- | What biomarkers can stratify ALS patients most likely to respond to ferroptosis- | open | 0.80 | 0.71 | 2026-04-17 | 0 | | clinical-research |
| gap-debate-20260417- | Why do GPX4-independent ferroptosis protection pathways (FSP1/AIFM2, GCH1/BH4) f | resolved | 0.85 | 0.71 | 2026-04-17 | 0 | | molecular-biology |
| gap-debate-20260417- | Is ferroptosis the primary driver of motor neuron death in ALS or an epiphenomen | partially_addressed | 0.90 | 0.70 | 2026-04-17 | 0 | | neurodegeneration |
| gap-microglial-subty | Microglial subtypes in neurodegeneration — friend vs foe | partially_addressed | 0.75 | 0.00 | 2026-04-17 | 0 | | neurodegeneration |
| gap-20260416-220243 | Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma | partially_addressed | 0.90 | 0.00 | 2026-04-16 | 0 | | neurodegeneration |
| gap-ferroptosis-mnd- | Ferroptosis in ALS and Motor Neuron Disease: GPX4, Lipid Peroxidation, and Iron | partially_addressed | 0.87 | 0.85 | 2026-04-16 | 1 | 2026-04-26 | neurodegeneration |
| gap-20260416-133111 | test | partially_addressed | 0.90 | 0.00 | 2026-04-16 | 0 | | neurodegeneration |
| gap-epigenetic-compa | Comparative epigenetic signatures: DNA methylation age acceleration and histone | partially_addressed | 0.75 | 0.00 | 2026-04-16 | 0 | | neurodegeneration |
| gap-20260416-121711 | How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle | partially_addressed | 0.90 | 0.00 | 2026-04-16 | 0 | | neurodegeneration |
| gap-bbb-tjp-20260416 | Blood-brain barrier tight junction disruption by neuroinflammatory cytokines | partially_addressed | 0.85 | 0.00 | 2026-04-16 | 0 | | neurodegeneration |
| gap-20260415-222947 | Does APOE4 drive tau propagation | partially_addressed | 0.90 | 0.00 | 2026-04-15 | 0 | | neurodegeneration |
| gap-20260415-221737 | test debate | partially_addressed | 0.90 | 0.00 | 2026-04-15 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What is the mechanistic basis for the synergistic interaction between CYP46A1 C | open | 0.74 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What mechanisms explain why CYP46A1 TT, but not CC, genotype correlates with hig | open | 0.79 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | Why does AMPK specifically regulate lipid homeostasis differently in tauopathy v | open | 0.75 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | How does lipid droplet accumulation mechanistically impair microglial phagocytos | open | 0.79 | 0.00 | 2026-04-12 | 0 | | neuroinflammation |
| gap-pubmed-20260412- | What molecular mechanisms drive the transfer of unsaturated lipids from tauopath | open | 0.80 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | How do circadian clock gene changes translate to improved glycemic control and a | open | 0.79 | 0.00 | 2026-04-12 | 0 | | metabolic-neuroscience |
| gap-pubmed-20260412- | What molecular mechanisms link dairy protein intake to circadian clock gene upre | open | 0.77 | 0.00 | 2026-04-12 | 0 | | circadian-neurobiology |
| gap-pubmed-20260412- | What factors enable healthy astrocytes to rescue OPTN(E50K) RGC neurodegeneratio | open | 0.83 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | How do OPTN(E50K) astrocytes induce neurodegenerative properties in healthy RGCs | open | 0.85 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What molecular mechanisms underlie autophagy dysfunction in OPTN(E50K) astrocyte | open | 0.82 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What determines the relative contribution of PARP versus caspase pathways in SiN | open | 0.77 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | How do Parthanatos and caspase-dependent apoptotic pathways interact mechanistic | open | 0.83 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What signals trigger the clonal expansion of specific venous capillary ECs/EPCs | open | 0.76 | 0.00 | 2026-04-12 | 0 | | cerebrovascular |
| gap-pubmed-20260412- | What determines the brain-specific predilection of CCM lesions despite systemic | open | 0.75 | 0.00 | 2026-04-12 | 0 | | cerebrovascular |
| gap-pubmed-20260412- | How does Cav1/caveolae mechanistically regulate mTORC1 protein trafficking and c | open | 0.83 | 0.00 | 2026-04-12 | 0 | | cerebrovascular |
| gap-pubmed-20260412- | Why does ozone exposure show no association with any AD-related biomarkers despi | open | 0.74 | 0.00 | 2026-04-12 | 0 | | environmental-neurotoxicity |
| gap-pubmed-20260412- | What mechanisms explain PM₂.₅-induced tau pathology in APOE4+ carriers independe | open | 0.77 | 0.00 | 2026-04-12 | 0 | | neuroinflammation |
| gap-pubmed-20260412- | Why does PM₂.₅ exposure increase tau pathology in APOE4+ carriers but not affect | resolved | 0.80 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What determines the selectivity of EZH2 inhibition for inducing pyroptosis in GB | open | 0.79 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | How does EZH2-STAT3-mediated pyroptosis affect the broader GBM tumor microenviro | open | 0.83 | 0.00 | 2026-04-12 | 0 | | neuroinflammation |
| gap-pubmed-20260412- | What are the molecular mechanisms by which EZH2 regulates STAT3 in the context o | open | 0.82 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What are the specific therapeutic strategies to target this RNA-based disease me | resolved | 0.85 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | How does the intron-retained RNA isoform mechanistically reduce glucocerebrosida | investigating | 0.87 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | Why is the African ancestry-specific GBA1 risk variant almost completely absent | open | 0.80 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | How do synaptic vesicle endocytosis defects mechanistically link to cognitive dy | open | 0.77 | 0.00 | 2026-04-12 | 0 | | synaptic-biology |
| gap-pubmed-20260412- | Why do GBA mutations specifically target layer 5 cortical neurons for phospho-α- | open | 0.80 | 0.00 | 2026-04-12 | 0 | | synaptic-biology |
| gap-pubmed-20260412- | What molecular mechanisms drive α-synuclein-independent cognitive deficits in GB | open | 0.85 | 0.00 | 2026-04-12 | 0 | | neurodegeneration |
| gap-pubmed-20260412- | What determines when Rab27 effectors switch from promoting to restricting exocyt | open | 0.75 | 0.00 | 2026-04-12 | 0 | | synaptic-biology |
| gap-pubmed-20260412- | How do multiple Rab27 effectors coordinate within single cells to regulate the c | open | 0.79 | 0.00 | 2026-04-12 | 0 | | synaptic-biology |